Recent news coverage includes the launch of an antibacterial product to aid Covid-19 prevention and control, completion of acquisitions, and financial results announcements in 2021. No recent news specific to AiXin Life's operations beyond 2021 was found in the latest business news.

• AiXin Life International, Inc. launched an antibacterial product to facilitate prevention and control of Covid-19 in December 2021 [N8].
• The company announced completion of acquisitions and financial results for the third quarter ended September 30, 2021 [N8].
• AiXin Life announced acquisitions of a hotel and pharmacy chain in 2021 [N8].
• The company organized the China Healthcare & Nutrition Industry Development Forum in Beijing in May 2021 [N8].
• AiXin Life was welcomed to OTCQX in January 2021 [N8].

AiXin Life's integrated approach to product development, manufacturing, and multi-channel distribution positions it to capitalize on the growing health and wellness market in China. Its acquisitions of pharmacies and a manufacturing facility with R&D capabilities provide a foundation for innovation and quality control. The company's focus on personalized customer service, loyalty programs, and educational events can strengthen customer relationships and brand loyalty. Expansion into complementary healthcare services such as nursing homes and clinics could diversify revenue streams. The company's ability to rapidly develop and introduce new products based on customer feedback may provide a competitive edge.

The company has incurred significant net losses and working capital deficits, raising concerns about its ability to sustain operations without additional financing. The health and wellness market in China is highly fragmented and competitive, with many established players and rapidly changing consumer preferences. Brand recognition for AiXin Life's products remains limited. Liquidity ratios indicate potential financial stress. Dependence on acquisitions and expansion plans introduces execution risks. Regulatory changes and supply chain fluctuations could impact product availability and costs. Failure to effectively compete or manage costs could adversely affect financial performance and market position.

AiXin Life's moat is based on its vertically integrated business model combining research, development, manufacturing, and multi-channel distribution in the Chinese health and wellness market. Its in-house R&D and manufacturing capabilities, including a certified facility and experienced personnel, enable product innovation and quality control. The omni-channel approach, including company-owned pharmacies and direct marketing teams, provides personalized customer engagement and loyalty programs that foster customer retention and word-of-mouth distribution. The company's strategy to educate customers and employees enhances product differentiation. However, brand recognition is still developing, and the market is highly competitive with many established players, which may limit the moat's strength.

• Ongoing Net Losses and Liquidity Concerns: AiXin Life reported net losses in 2025 and 2024 and had a working capital deficit as of December 31, 2025. Liquidity ratios as of March 31, 2026 indicate potential financial stress, raising substantial doubt about the company's ability to continue as a going concern without additional financing [S1][S2].
• Highly Competitive Market: The health and wellness market in China is large, fragmented, and intensely competitive, with many established players including specialty retailers, supermarkets, drugstores, mass merchants, multi-level marketing organizations, and online merchants. This competition could adversely affect AiXin Life's market share and growth prospects [S1].
• Brand Recognition and Market Penetration: AiXin Life's products and brand names have yet to achieve widespread recognition, which may limit its ability to compete effectively against well-established brands [S1].
• Execution Risks in Expansion and Acquisitions: The company's strategy involves acquisitions and expansion into new healthcare services such as nursing homes and clinics. Execution risks include integration challenges, regulatory compliance, and operational management [S1].
• Supply Chain and Raw Material Price Fluctuations: Raw materials for manufacturing are subject to price fluctuations and supply-demand issues. The company does not enter into long-term contracts, which may expose it to cost volatility [S1].

• AiXin Life International, Inc. is a Colorado holding company conducting substantially all operations through subsidiaries in the People's Republic of China (PRC).
• The company focuses on health and wellness products targeting the growing Chinese middle class, including healthcare, nutritional products, wellness supplements, herbs, traditional Chinese remedies, functional products like weight management and probiotics, foods, and drinks.
• AiXin Life operates an omni-channel business model generating revenue through retail and wholesale product sales, company-owned pharmacies, direct marketing, and online activities.
• Subsidiaries include AiXinZhonghong (direct marketing and distribution), Chengdu Aixintang Pharmacies (operates eight pharmacies), Yunnan Runcangsheng (R&D, manufacturing, and wholesale of health and wellness products), and AiXin Hotel (hotel lease operations).
• The company acquired nine pharmacies in Chengdu in September 2021 and operates eight currently, using them for product distribution and as learning centers.
• In September 2022, AiXin Life acquired Yunnan Runcangsheng, which operates a 2,946 square meter production facility with R&D centers, extraction facilities, workshops, and planting facilities for key ingredients.
• Yunnan Runcangsheng has over 30 brand names and develops products targeting ailments related to lifestyle changes in China such as hypertension and obesity.
• AiXin Life leases a hotel in Chengdu since February 2024, covering approximately 18,000 square meters, and terminated a previous hotel lease in March 2024.
• The company aims to expand its healthcare market presence in China through product line expansion, acquisitions of pharmacies and retail outlets, and potentially operating nursing homes and clinics.
• AiXin Life's strategy includes developing recognized brand names, offering proprietary and third-party branded products, and providing customer education and support.
• The company emphasizes product development and innovation with in-house scientists, nutritionists, formulators, and quality control experts at Yunnan Runcangsheng.
• AiXin Life uses a differentiated customer experience with well-trained team members providing personalized service, coaching, and education on healthy lifestyles and product benefits.
• The company operates loyalty programs to reward customers and incentivize product distribution through independent marketers.
• AiXin Life organizes educational seminars and marketing events at its hotel to increase customer loyalty and educate team members.
• The omni-channel model integrates physical stores, pharmacies, direct marketing, wholesale, and online sales to provide a seamless customer experience.
• The company maintains vertical integration with research, development, manufacturing, and direct customer feedback to rapidly develop new products.
• Manufacturing facilities comply with national health food and pharmaceutical standards (GMP) and have ISO and HACCP certifications.
• Raw materials are generally readily available with price fluctuations; the company does not enter long-term contracts with suppliers.
• AiXin Life holds patents on certain manufacturing processes and uses multiple brand names, though brand recognition is still developing.
• The company incurred net losses in 2025 and 2024, with net losses of $2,042,463 and $2,768,341 respectively, and used net cash in operating activities of $2,034,331 and $1,628,834 respectively.
• As of December 31, 2025, the company had a working capital deficit of $7,476,418 and cash and cash equivalents decreased from $62,310 to $20,751 during 2025.
• The company had cash and cash equivalents of $37,677,000 and current assets of $1,054,805,000 as of March 31, 2026, with current liabilities of $8,965,264,000 resulting in a current ratio of 0.12 and a cash ratio of 0.
• Net income for the quarter ended March 31, 2026 was a loss of $531,728, and basic and diluted EPS were -$0.021 per share.
• The health and wellness market in China is highly competitive and fragmented, with competition from specialty retailers, supermarkets, drugstores, mass merchants, multi-level marketing organizations, online merchants, and others.
• Marketing efforts include person-to-person marketing, educational events, social gatherings, online informational videos, social media posts, and loyalty programs.
• The company offers a customer satisfaction guarantee allowing returns or exchanges of unopened products with certain fees.
• Recent news includes the launch of an antibacterial product to facilitate prevention and control of Covid-19 in December 2021.
• The company announced completion of acquisitions and financial results for the third quarter ended September 30, 2021.
• AiXin Life announced acquisitions of a hotel and pharmacy chain in 2021.
• The company organized the China Healthcare & Nutrition Industry Development Forum in Beijing in May 2021.
• AiXin Life was welcomed to OTCQX in January 2021.